.jpg?format=webp&width=780)
Pioglitazone, an effective and affordable drug, not only improves glycaemic control by reducing insulin resistance but also enhances beta cell function, leading to prolonged benefits. It shows positive effects on cardiovascular risk factors and reduces cardiac events in diabetic patients. Non-diabetic, insulin-resistant individuals experience reduced recurrence of transient ischaemic attack and stroke. Moreover, pioglitazone improves diastolic function in early-stage heart failure and lowers the incidence of atrial fibrillation by suppressing atrial remodeling.
Like
Save
Share